Aptose Biosciences Management

Management criteria checks 2/4

Aptose Biosciences' CEO is William Rice, appointed in Oct 2013, has a tenure of 10.58 years. total yearly compensation is $925.59K, comprised of 67.4% salary and 32.6% bonuses, including company stock and options. directly owns 0.22% of the company’s shares, worth $42.03K. The average tenure of the management team and the board of directors is 1.9 years and 10.6 years respectively.

Key information

William Rice

Chief executive officer

US$925.6k

Total compensation

CEO salary percentage	67.4%
CEO tenure	10.6yrs
CEO ownership	0.2%
Management average tenure	1.9yrs
Board average tenure	10.6yrs

Recent management updates

Recent updates

Aptose Shares Sell Off As The Market Wanted More Than Further Signs And Portents

Dec 08

Aptose Shares Look Undervalued Ahead Of Value-Driving Efficacy Data

Nov 12

CEO Compensation Analysis

How has William Rice's remuneration changed compared to Aptose Biosciences's earnings?
Date	Total Compensation	Salary	Company Earnings
Dec 31 2023	US$926k	US$624k	-US$51m
Sep 30 2023	n/a	n/a	-US$49m
Jun 30 2023	n/a	n/a	-US$48m
Mar 31 2023	n/a	n/a	-US$44m
Dec 31 2022	US$2m	US$599k	-US$42m
Sep 30 2022	n/a	n/a	-US$56m
Jun 30 2022	n/a	n/a	-US$58m
Mar 31 2022	n/a	n/a	-US$61m
Dec 31 2021	US$2m	US$582k	-US$65m
Sep 30 2021	n/a	n/a	-US$56m
Jun 30 2021	n/a	n/a	-US$58m
Mar 31 2021	n/a	n/a	-US$60m
Dec 31 2020	US$12m	US$582k	-US$55m
Sep 30 2020	n/a	n/a	-US$48m
Jun 30 2020	n/a	n/a	-US$42m
Mar 31 2020	n/a	n/a	-US$32m
Dec 31 2019	US$2m	US$562k	-US$26m
Sep 30 2019	n/a	n/a	-US$25m
Jun 30 2019	n/a	n/a	-US$24m
Mar 31 2019	n/a	n/a	-US$28m
Dec 31 2018	US$2m	US$540k	-US$29m
Sep 30 2018	n/a	n/a	-US$26m
Jun 30 2018	n/a	n/a	-US$23m
Mar 31 2018	n/a	n/a	-US$15m
Dec 31 2017	US$983k	US$520k	-US$12m

Compensation vs Market: William's total compensation ($USD925.59K) is above average for companies of similar size in the US market ($USD667.63K).

Compensation vs Earnings: William's compensation has been consistent with company performance over the past year.

CEO

William Rice (64 yo)

10.6yrs

Tenure

US$925,591

Compensation

Dr. William G. Rice, Ph D., had served as an Independent Director of Oncolytics Biotech Inc. since June 08, 2015 until June 30, 2021. He has been the Chief Executive Officer and President of Aptose Bioscie...

Leadership Team

Name	Position	Tenure	Compensation	Ownership
William Rice	Chairman	10.6yrs	US$925.59k	0.22% $ 42.0k
Fletcher Payne	Senior VP	1.9yrs	US$624.24k	0.047% $ 9.0k
Rafael Bejar	Senior VP & Chief Medical Officer	4.3yrs	US$653.24k	0.047% $ 9.0k
Marc Wiles	Senior Vice President of Regulatory Affairs	less than a year	no data	no data
Brooks Ensign	VP & Controller	1.3yrs	no data	no data

1.9yrs

Average Tenure

60yo

Average Age

Experienced Management: APTO's management team is not considered experienced ( 1.9 years average tenure), which suggests a new team.

Board Members

Name	Position	Tenure	Compensation	Ownership
William Rice	Chairman	10.6yrs	US$925.59k	0.22% $ 42.0k
Mark Vincent	Independent Director	16.7yrs	US$117.68k	0.0027% $ 530.9
Bernd Seizinger	Independent Director	1.7yrs	US$117.17k	0.11% $ 20.9k
Denis Burger	Lead Independent Director	16.7yrs	US$172.17k	0.0092% $ 1.8k
Stephen Howell	Member of Scientific Advisory Board	no data	no data	no data
Daniel Von Hoff	Member of Scientific Advisory Board	no data	no data	no data
Erich Platzer	Independent Director	9.4yrs	US$113.67k	0.21% $ 41.4k
Warren Whitehead	Independent Director	13.1yrs	US$122.68k	0.0064% $ 1.2k
Brian Druker	Chairman of Scientific Advisory Board	10.6yrs	no data	no data
Michael Andreeff	Member of Scientific Advisory Board	9.2yrs	no data	no data
Carol Ashe	Independent Director	5.8yrs	US$124.39k	0% $ 0

10.6yrs

Average Tenure

70.5yo

Average Age

Experienced Board: APTO's board of directors are seasoned and experienced ( 10.6 years average tenure).

Aptose Biosciences Management

Management criteria checks 2/4

Key information

Recent management updates

Aptose Biosciences Inc., Annual General Meeting, May 28, 2024

Aptose Biosciences Inc. Appoints Fletcher Payne as Chief Business Officer

Independent Director recently bought US$53k worth of stock

Insufficient new directors

Aptose Biosciences Inc. Appoints Bernd R. Seizinger to the Board of Directors

Aptose Appoints Fletcher Payne as Chief Financial Officer

Recent updates

Aptose Biosciences Receives a Letter from the Nasdaq Stock Market Stating the Company Was Not in Compliance with Nasdaq Listing Rule 5550(b)(1)

New major risk - Negative shareholders equity

Aptose Biosciences Inc., Annual General Meeting, May 28, 2024

Aptose Biosciences Inc. to Report Q4, 2023 Results on Mar 26, 2024

Aptose Biosciences Receives Deficiency Letter from The Nasdaq Stock Market LLC

Aptose Biosciences Inc. announced that it has received $4 million in funding from Hanmi Pharm. Co., Ltd.

New major risk - Shareholder dilution

Aptose Biosciences Inc. has completed a Follow-on Equity Offering in the amount of $16.799998 million.

Aptose Biosciences Inc. has filed a Follow-on Equity Offering in the amount of $16.799998 million.

Aptose Tuspetinib Clinical Data Featured in Oral Presentation at the 2023 ASH Annual Meeting

Aptose Biosciences Inc. Appoints Fletcher Payne as Chief Business Officer

Aptose Tuspetinib Clinical Data Selected for Oral Presentation at the 2023 ASH Annual Meeting

Aptose Biosciences Inc. Presents Highlights from Clinical Update Webcast Featuring Latest Available Data on AML Drug Tuspetinib

Aptose Biosciences Inc. to Report Q3, 2023 Results on Nov 09, 2023

Aptose to Hold Clinical Update and KOL Data Review of AML Drug Tuspetinib on Monday, October 30th

New major risk - Share price stability

Independent Director recently bought US$53k worth of stock

Aptose Biosciences Inc. Provides A Recent Update from an Ongoing Aptivate Phase 1/2 Clinical Trial with the Company's Lead Agent, Tuspetinib

New minor risk - Share price stability

Aptose Biosciences Inc. announced that it expects to receive CAD 7 million in funding from Hanmi Science Co., Ltd.

Aptose Biosciences Inc. to Report Q2, 2023 Results on Aug 10, 2023

Aptose Biosciences Meets Nasdaq Minimum Bid Price Compliance

Aptose Biosciences Inc. Presents Highlights from Clinical Update

Aptose Biosciences Inc. announced that it expects to receive CAD 25 million in funding

Forecast to breakeven in 2025

Aptose Biosciences Inc. Updates Clinical Responses, Breadth of Activity, and Safety Across Four Dose Levels of Tuspetinib in Difficult-to-Treat Acute Myeloid Leukemia Populations

Aptose Biosciences Inc. Treats First Patient with Continuous Dosing of New “G3” Formulation of Luxeptinib

Insufficient new directors

Aptose Biosciences Inc. to Report Q3, 2022 Results on Nov 01, 2022

Aptose Biosciences Inc. Appoints Bernd R. Seizinger to the Board of Directors

Aptose Biosciences Inc.’s New G3 Formulation of Luxeptinib Boosts Bioavailability

Aptose Biosciences Q2 2022 Earnings Preview

Aptose Biosciences Receives a Deficiency Letter from the Nasdaq Listing Qualifications Department Regarding Minimum Bid Price Requirement

Aptose Biosciences Inc. to Report Q2, 2022 Results on Aug 02, 2022

Aptose Biosciences Continues To Drift Without Thesis-Changing Data

Aptose Appoints Fletcher Payne as Chief Financial Officer

Aptose Receives Fast Track Designation for Hm43239 in Relapsed/Refractory Aml Patients and Flt3 Mutation

Insufficient new directors

Aptose Biosciences Inc. to Report Q1, 2022 Results on May 09, 2022

Aptose Biosciences Inc. Announces Resignation of Dr. Jotin Marango as Chief Financial Officer

Aptose Deep In The Doghouse Due To Lack Of Pipeline Progress

Aptose Biosciences Inc. Provides Update on APTO-253 Program

Independent Director recently bought US$316k worth of stock

Aptose Biosciences Inc. Announces HM43239 Demonstrates Durable Clinical Benefit in Acute Myeloid Leukemia

Insufficient new directors

Aptose: High Risk, High Reward. Watch Its Phase I Studies

Independent Director recently sold US$67k worth of stock

Aptose Biosciences (APTO) Presents Corporate Update at EHA 2021 - Slideshow

Aptose Presents Highlights from EHA2021 Virtual Congress During Corporate Update Event

Aptose Biosciences: An Assessment

Executive VP, Corporate Secretary, CFO & COO has left the company

Aptose Biosciences Inc. to Report Q4, 2020 Results on Mar 23, 2021

New 90-day low: US$3.98

Aptose Shares Sell Off As The Market Wanted More Than Further Signs And Portents

New 90-day high: US$6.67

Aptose Shares Look Undervalued Ahead Of Value-Driving Efficacy Data

Aptose Biosciences Inc. to Present CG-806 and APTO-253 Data At the 2020 Ash Annual Meeting

Aptose Biosciences Inc. to Report Q3, 2020 Results on Nov 10, 2020

New 90-day low: US$4.75

Aptose Initiates Dosing of CG-806 in Patients with Acute Myeloid Leukemia

New 90-day low - US$4.88

Aptose Biosciences Inc. to Report Q2, 2020 Results on Aug 04, 2020

Aptose Biosciences Inc. has completed a Follow-on Equity Offering in the amount of $55.125 million.

CEO Compensation Analysis

CEO

Tenure

Compensation

Leadership Team

Average Tenure